---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-26-000004"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:32:59.647481+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio subsidiary terminates license deal with ImmuneOnco for AXN-2510 and AXN-27M

## Summary
- Axion Bio (Instil Bio subsidiary) terminated License and Collaboration Agreement with ImmuneOnco effective Jan 5, 2026.
- Agreement, dated Aug 1, 2024, granted Axion ex-China rights to AXN-2510 and AXN-27M.
- No details provided on termination reason or financial impact on Instil Bio.

## SEC filing metadata
- accession: 0001789769-26-000004
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/0001789769-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/til-20260105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-26-000004
- JSON: https://secwatch.observer/filing/0001789769-26-000004.json
- Plain text: https://secwatch.observer/filing/0001789769-26-000004.txt

## Key facts
- Material Agreements
  Instil Bio, Inc. terminated License and Collaboration Agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (effective 2026-01-05).
  - Action: termination
  - Agreement: license
  - Counterparty: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
  - Effective: 2026-01-05
  source text: Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License and Collaboration Agreement dated August 1, 2024 between ImmuneOnco and Axion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000004/0001789769-26-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.